Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients

• Published in: Molecular and clinical oncology 2015-09, Vol.3 (5), p.1088-1092
• Main Authors: WANG, ZHI, DANG, CHENGXUE, ZHU, KUN, ZHANG, YONG, CHANG, DONGMIN, XIA, PENG, SONG, YONGCHUN, LI, KANG
• Format: Article
• Language: English
• Subjects: Anticoagulants; Breast cancer; Cancer therapies; Chemotherapy; Clinical trials; Confidence intervals; Cyclophosphamide; D-dimer; deep vein thrombosis; Drug therapy; Epirubicin; fluorouracil; Genetic aspects; Health aspects; Health risk assessment; Hypotheses; Laboratories; Medical prognosis; Oncology; Studies; Thrombosis; Variance analysis
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2015.584

The occurrence of chemotherapy-induced alterations in markers of haemostasis during chemotherapy has been reported previously. However, the change of the haemostasis markers in the cyclophosphamide, epirubicin and fluorouracil (CEF) regimen remains unclear. The aim of the present study was to identify the change of the haemostasis markers during systemic chemotherapy (600 mg/m2 cyclophosphamide, 80 mg/m2 epirubicin and 500 mg/m2 fluorouracil; four courses over 21 days) to investigate its influence on the haemostasis markers of breast cancer patients and to discuss the requirement of anticoagulation therapy. D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT) and fibrinogen (FIB) values were obtained before chemotherapy and on days 1, 4, 7 and 21. The results show that PT, D-dimer and FIB were not prolonged prior to chemotherapy compared to that under the control. APTT was prolonged until day 4. The levels of D-dimer and APTT were significantly higher compared to those of the breast cancer patients before receiving chemotherapy and controls on days 1, 4, 7 and 21 after chemotherapy. Alteration of the haemostasis markers occurred in the breast cancer patients under the CEF chemotherapy regimen. As there is an increased risk of deep vein thrombosis and pool prognosis of cancer patients, anticoagulant therapy should be considered.